iCAD Introduces ProFound AI™ for 2D Mammography in Europe
Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France
NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France.
“iCAD is at the forefront of the fight against breast cancer. We bring powerful solutions to physicians across Europe so women everywhere can benefit from earlier detection,” explains Michele Debain, MBA, Sr. Director, Business Development Europe, iCAD. “Our first ProFound AI product was for tomosynthesis; this solution was created to help physicians overcome their workflow issues of reading extensive amounts of data and reduce the likelihood of missing malignancies. Today, we are thrilled to introduce our second ProFound AI product for 2D Mammography, which promises to assist physicians in all breast screening exams, especially the challenging dense breast cases, to bring precise detection and reduce false positives. ProFound AI for Mammography is an extremely valuable tool for women, physicians and all breast screening practices.”
ProFound AI is available for both mammography and tomosynthesis modalities; it is a high-performance, deep-learning, breast cancer detection and workflow solution that offers benefits to radiologists and patients alike. ProFound AI for DBT is clinically proven to improve cancer detection rates by 8 percent, reduce unnecessary patient recall rates by 7.2 percent, and slash reading time for radiologists by 52.7 percent and up to 57.4 percent for dense breast 3D image analysis.1
“The arrival of the ProFound AI platform has completely changed the way we read tomosynthesis cases. It is a very powerful and extremely useful tool that improves our diagnostic confidence; especially for subtle lesions and dense breasts,” according to Dr. Patrick Toubiana, Radiologist, President and Cofounder at the C.S.E. Centre Imagerie Médicale Numérique in Paris. “In addition, ProFound AI allows us to optimize our workflow for better reading comfort and a reduction of the interpretation time of the tomosynthesis slices. Today, ProFound AI is a real asset in our daily practice that we could not do without.”
ProFound AI for 2D Mammography and ProFound AI for DBT were designed to rapidly and accurately analyze each image and provide radiologists with key information, such as certainty of finding lesion and case scores, which assists in clinical decision-making and prioritizing caseloads. Featuring the latest in deep-learning artificial intelligence, the platform also allows for continuously improved performance via ongoing updates.
“The ProFound AI software platform is the result of many years of research and development to create a deep-learning algorithm that analyzes each image with unrivaled accuracy,” according to Stacey Stevens, President of iCAD. “With more than 4,000 sites worldwide to-date, the growing adoption of our technology demonstrates iCAD’s rapidly expanding global presence and reaffirms our company’s commitment to improving women’s health worldwide.”
ProFound AI for DBT was FDA cleared, CE marked, and Health Canada licensed in 2018. ProFound AI for 2D Mammography is pending CE Mark in the EU. For more information, visit www.icadmed.com.
- Hoffmeister, J. (2018). Artificial Intelligence for Digital Breast Tomosynthesis – Reader Study Results. [White paper]. Accessed June 4, 2019 via https://www.icadmed.com/assets/dmm253-reader-studies-results-rev-a.pdf
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Jessica Burns, iCAD
LifeSci Advisors, on behalf of iCAD, Inc.
Jeremy Feffer, (212) 915-2568
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Cable Onda Financial Update18.10.2019 08:45:00 CEST | Press release
Cable Onda Financial Update Luxembourg, 18 October 2019 – Millicom announced today that its subsidiary, Cable Onda S.A. (“Cable Onda”), a leading provider of Mobile, Pay TV, fixed broadband, internet and telephony services in both the residential and B2B sectors in Panama, has mandated Goldman Sachs & Co. LLC and J.P. Morgan as Global Coordinators, and BNP Paribas, Morgan Stanley and Scotiabank as Joint Bookrunners for a potential benchmark senior unsecured 144A/RegS USD bond transaction, subject to market conditions. In relation with this planned transaction, Cable Onda informs the market that it expects revenue of approximately $313.0 million to $315.0 million and EBITDA of approximately $149.0 million to $151.0 million on a consolidated basis for the nine months ended September 30, 2019. Cable Onda’s actual operating results remain subject to the completion of its quarter-end closing process, which includes review by management and its board of directors. These expected nine-month r
Orange Belgium invites investors and analysts to participate to its Q3 results conference call on October 23, 201918.10.2019 08:37:00 CEST | Press release
Orange Belgium will publish its results for the third quarter of 2019 on Wednesday, October 23 at 07:00 CET. Orange Belgium Investor Relations is pleased to invite investors and analysts to participate in a conference call hosted by: Michaël Trabbia, CEO Arnaud Castille, CFO Eric Chang, Investor Relations The conference call will start at 10:00 am CET (9:00 am UK / 4:00 am EST). To access the call, please dial one of the following numbers 5-10 minutes prior to the start of the conference call in order to avoid waiting time. Consequently register with following pin code: 28900648# and provide your name and the company you work for. Belgium +32 24035816 Canada +1 4162164194 France +33 170710159 Germany +49 69222225429 Ireland +353 15060451 Italy +39 0236013817 Luxembourg +352 27300163 Netherlands +31 207095119 Spain +34 911140101 Switzerland +41 445831805 United Kingdom +44 2071943759 United States +1 6467224916 The recorded session will be available after the conference call and can be
Schibsted ASA (SCHA/SCHB) - Invitation to the presentation of Q3 2019 Results18.10.2019 08:30:00 CEST | Press release
We hereby invite you to participate at the presentation of the Q3 2019 reports of Schibsted Media Group on 25 October 2019 Quarterly Earnings Release Time: 25 October 2019 at 07.00 CET Interim report, presentation materials, and spreadsheet with key figures and analytical information will be made available on the investor relations pages at https://www.schibsted.com/ir/. Results Presentation Time: October 2019 at 09.00 CET Location: Schibsted’s premises in Akersgata 55, Oslo, Norway. The presentation will be webcasted live at https://www.schibsted.com/ir/. It will be presented in English. Participants can send in written questions through the webcast player. CEO Kristin Skogen Lund and EVP CFO Trond Berger will present. A recording of the presentation will be available on our web site shortly after the live webcast has ended. Conference call for investors and analysts - Q&A session Time: 25 October 2019 at 14.00 CET Questions relating to the results will be answered in a conference cal
Hofseth Biocare ASA: ENTERS INTO A CONSULTANCY AGREEMENT WITH JAMES BERGER – CONTEMPLATED US LISTING18.10.2019 08:05:00 CEST | Press release
Hofseth BioCare ASA ("HBC") has today entered into a consultancy agreement with James Berger (through his company Nevera AG). Mr. Berger is a dual British and Italian citizen currently residing in Switzerland who has previously worked as an investment banker with Goldman Sachs International (London), JP Morgan (London), MAN Investments PLC and Millennium Capital Management LLC. He has a broad network with the largest investment banks and institutional investors in Europe and globally. Mr. Berger has already successfully assisted HBC with its oversubscribed private placement of NOK 118 million that was directed towards international private investors and institutional funds. He has recently also facilitated the sale of additional shares in HBC from certain existing shareholders to new international investors. Under the consultancy agreement, Mr. Berger will assist HBC with certain intermediary services, in establishing a wider base of international investors. Mr. Berger and HBC believe
Yara announces share buy-backs18.10.2019 08:02:00 CEST | Press release
Oslo, 18 October 2019: Yara International ASA plans to buy back 0.5% of its outstanding shares by the end of 2019. Including the proportional redemption of shares owned by the Norwegian state, the total buyback and redemption will amount to approximately 0.8% of shares outstanding, equivalent to approximately NOK 800 million at today’s share price. Yara's targeted capital structure is a mid- to long-term Net debt/EBITDA range of 1.5-2.0 and a net debt/equity ratio below 0.60. Subject to these requirements, Yara's ordinary dividend shall be 50% of net income. Shareholder returns are distributed primarily as cash, with share buy-backs as a supplemental lever. Yara’s net debt/EBITDA as of 30 September 2019 would be close to 2.0 including the full effect of the announced buyback. The buy-backs are part of a program authorized by the Annual General meeting held 7 May 2019, which authorized Yara to buy back up to 5% (13,620,131 shares) of its share capital before its 2020 Annual General Meet
Yara med høyere resultat, operasjonell og kommersiell forbedring18.10.2019 08:00:00 CEST | Pressemelding
Oslo, 18. oktober 2019: Nettoresultat etter minoritetsinteresser for tredje kvartal var på USD 74 millioner (USD 0,27 per aksje), mot USD 98 millioner (USD 0,36 per aksje) for samme periode i fjor. Korrigert for valutaeffekter og spesielle poster var resultatet på USD 0,94 per aksje, mot USD 0,50 per aksje i tredje kvartal 2018. EBITDA eksklusive spesielle poster for tredje kvartal var på USD 630 millioner, opp fra USD 402 millioner ett år tidligere, og reflekterer høyere nitrogen oppgraderingsmarginer og sterke premium-leveranser. «Yara leverer betydelig bedre resultater i andre kvartal, med EBITDA eksklusive spesielle poster og IFRS 16 opp 49 %. Resultatet reflekterer lavere energikostnader, høyere produksjon og sterke premium-leveranser» sier Svein Tore Holsether, konsernsjef i Yara. «Jeg er fornøyd med at vi leverer resultatforbedring innen alle forretningsområder, med sterkest økning i New Business. Yaras avkastning fortsetter å øke, og hovedprioriteten fremover vil fortsatt være